Pliant reports updated Phase 1 data for PLN-101095 cancer treatment

April 18, 2026 1:31 PM

Pliant Therapeutics Inc. (NASDAQ: PLRX) presented updated results from its Phase 1 trial of PLN-101095 combined with pembrolizumab in patients ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found